One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Inclusion/ Exclusion Criteria Key Inclusion Criteria: * Adult participant (18 years and over) * treated for one of the following conditions: RA, AS, PsA, CD, UC. * either active substance naïve or treated with the originator or another biosimilar at baseline. * for whom the treating physician has decided to treat by (naïve) or switch from originator or another biosimilar to Flixabi or Imraldi. * participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort. * Paediatric participants (6-17 years): * treated for one of the following conditions: CD, UC. * either active substance naïve or treated with another biosimilar at baseline. * for whom the treating physician has decided to treat by (naïve) or switch to Flixabi (for both indications) or Imraldi (only for Crohn's disease). * participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort. Key Exclusion Criteria: * Participant treated for psoriasis. * Participant who are not to be followed up in the same investigator site for 2 years after baseline. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.